Eurosarc Trial of Linsitinib in Advanced Ewing Sarcoma
NCT02546544
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
16
Enrollment
OTHER
Sponsor class
Conditions
Relapsed Ewing Sarcoma
Refractory Ewing Sarcoma
Interventions
DRUG:
Linsitinib
Sponsor
University of Oxford
Collaborators
[object Object]
[object Object]
[object Object]
[object Object]